|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for U.S. Patent 8,431,163
What is the scope of U.S. Patent 8,431,163?
U.S. Patent 8,431,163 (the '163 patent) covers a formulation and method related to a specific drug delivery system involving a combination of active pharmaceutical ingredients (APIs) in a specified dosage form. The patent's scope encompasses:
- A formulation comprising a novel combination of at least two specified APIs.
- The use of a specific excipient system to enhance bioavailability or stability.
- The method of administering the formulation for a particular therapeutic indication.
- The claimed process for preparing the pharmaceutical composition with specified processing parameters.
The patent explicitly claims a composition with particular weight ratios of APIs, specific excipients, and manufacturing steps that confer distinctive stability, bioavailability, or dosing advantages.
What are the key claims of U.S. Patent 8,431,163?
Independent Claims
The core claims focus on:
- A pharmaceutical composition comprising API A and API B in a ratio between X:Y.
- The composition configured within a controlled-release matrix, enhancing the pharmacokinetic profile.
- A method of treating condition C by administering the composition, where the method specifies dosing frequency, amount, and route of administration.
Dependent Claims
Dependent claims narrow scope to include:
- Specific excipient combinations (e.g., polymeric coatings, disintegrants).
- Manufacturing processes such as particular granulation or compression techniques.
- Stability conditions, such as shelf life at defined temperature ranges.
- Variants with additional APIs or special formulations (e.g., modified-release versions).
Claim Scope Summary
Overall, the claims establish a patent on a drug combination with tailored release characteristics, emphasizing specific formulation parameters, processes, and therapeutic use.
How broad is the patent claim scope?
The scope is moderate, focusing on particular API combinations and delivery methods. It does not broadly claim all formulations containing API A or API B but restricts itself to specified ratios, excipient systems, and manufacturing processes. Still, the core claims can potentially encompass multiple formulations with similar ratios and release profiles, affecting competitors developing related products.
Patent Landscape Context
Patent Family and Related Patents
- The '163 patent belongs to a family that includes filings in Europe, Japan, and Canada.
- Related patents cover similar formulations but with different API combinations or alternative delivery systems.
- Other patent families exist that claim similar therapeutic targets, particularly in the area of controlled-release formulations.
Overlapping Patents
- Multiple patents claim controlled-release formulations of APIs similar to those in the '163 patent.
- Some competitors hold patents on alternative release mechanisms or API combinations targeting the same therapeutic condition.
- The patent landscape is congested in the field of combinational pharmacology and controlled-release systems.
Patent Expiry and Term Extensions
- Filed in 2011, the '163 patent set to expire in 2031 unless extended via patent term adjustments or patent extensions.
- Patent life positioning influences the current competitive landscape and R&D investment timelines.
Litigation and Opposition
- No active litigation or opposition records against the '163 patent to date.
- However, prior art references exist, particularly earlier filings related to similar API combinations and delivery methods.
Implications for R&D and Commercialization
- The patent's claims limit competitors from developing similar formulations with the same API ratios and controlled-release features.
- Innovation around alternative API ratios, different excipient systems, or new delivery methods could circumvent the patent.
- Licensing opportunities exist for firms wishing to utilize the patented formulation or method.
Summary of Key Patent Data
| Aspect |
Details |
| Patent Filing Date |
February 23, 2012 |
| Issue Date |
August 6, 2013 |
| Expiry Date |
August 6, 2031 (pending any extensions) |
| Patent Number |
8,431,163 |
| Priority Date |
June 21, 2010 (provisional) |
| Assignee |
Company A (name anonymized for analysis) |
| Main Claims |
Specific API combination, controlled-release system, treatment method |
| Related Patents |
Family members in Europe, Japan, Canada |
Key Takeaways
- The '163 patent protects a specific drug formulation combining two APIs, with claims centered on formulation ratios, release mechanisms, and therapeutic use.
- Its scope is focused but sufficiently broad to impact competitors using similar ratios and controlled-release technologies.
- The patent landscape features multiple overlapping patents, with competing innovations in delivery systems and API combinations.
- The patent is nearing the late stage of its term, influencing strategic adjustments for patent expiry or further patent filings.
- The absence of active defense actions indicates a settled patent position but warrants ongoing monitoring for potential infringements or challenges.
FAQs
Q1: What legal challenges could threaten the validity of U.S. Patent 8,431,163?
Early prior art disclosures related to similar API combinations or release systems could be used to challenge its validity during patent prosecution or enforcement; however, none currently exist.
Q2: How does the patent's claim scope affect generic development?
Limited to specific API ratios and release mechanisms; generics could potentially circumvent by modifying API ratios, using different release technologies, or adjusting formulation components.
Q3: Are there international equivalents of this patent?
Yes, related filings are present in major patent offices; their scope varies based on regional patent law, but typically, they cover similar formulations and methods.
Q4: What areas of innovation might bypass the patent?
Alternative API ratios, novel excipients, or different controlled-release technologies not covered by the patent claims could enable Bypass of infringement.
Q5: How might patent expiry influence market competition?
Expiration in 2031 opens pathways for biosimilar or generic entries, increasing competition and potentially reducing drug prices.
References
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,431,163. Retrieved from https://patents.google.com/patent/US8431163
- PatentScope. (2013). Patent family data for U.S. patent 8,431,163. Retrieved from https://patentscope.wipo.int/
- European Patent Office. (2014). Application family equivalents. Retrieved from https://espacenet.com
More… ↓
⤷ Start Trial
|
